Ajanta Pharma: Strong Pipeline, Margin Pause

May 02, 2025 | CMP: INR 2,691| Target Price: INR 3,180

Expected Share Price Return: 18.1% I Dividend Yield: 0.0% I Expected Total Return: 18.1%

Dev.%

BUY Sector View: Neutral

Choice

 Change in Estimates
 Image: Change

 Target Price Change
 Image: Change

 Recommendation
 Image: Change

 Company Info
 Image: Change

 BB Code
 AJP IN EQUITY

 Face Value (INR)
 2.0

 52 W High/Low (INR)
 3,486/2,022

 Mkt Cap (Bn)
 INR 337 / \$ 3.9

Shares o/s (I	Shares o/s (Mn)					125.4
3M Avg. Daily	/ Volume				1	1,70,619
Change in Es	stimates					
	FY26E			FY27E		
INR Bn	New	Old	Dev. (%)	New	Old D)ev. (%)
Revenue	51.8	52.2	(0.8)	59.0	59.6	(1.1)
EBITDA	14.6	15.4	(4.9)	17.4	18.1	(4.3)
EBITDAM %	28.3	20.5	(122)hnc	20 /	20 4 (100\bbc

A street we Os						
EFS	00.1	50.0	(0.2)	101.9	108.4	(0.1)
FPS	85.1	90.8	(6.2)	101.9	108 4	(6.1)
PAT	10.7	11.4	(6.2)	12.8	13.6	(6.1)
EBITDAM %	28.3	29.5	(122)bps	29.4	30.4	(100)bps
EBITDA	14.6	15.4	(4.9)	17.4	18.1	(4.3)
Revenue	51.8	52.2	(0.8)	59.0	59.6	(1.1)


Actual vs conse	liaua	
INR Bn	Q4FY25A	Consensus Est.
Povonuo	11 7	11 /

		Est.	
Revenue	11.7	11.4	2.6
EBITDA	3.0	3.2	-6.8
EBITDAM %	25.4	28.0	-256bps
PAT	2.3	2.9	-22.1

Key Financials	Key Financials									
INR Bn	FY23	FY24	FY25	FY26E	FY27E					
Revenue	37.4	42.1	46.5	51.8	59.0					
YoY (%)	12.0	12.5	10.4	11.5	13.9					
EBITDA	-3.7	11.5	12.6	14.6	17.4					
EBITDAM %	-9.9	27.4	27.1	28.3	29.4					
Adj PAT	-5.7	8.2	9.2	10.7	12.8					
EPS	-44.9	64.6	73.4	85.1	101.9					
ROE %	-16.7	22.9	24.3	22.0	20.8					
ROCE %	-12.1	17.6	18.4	17.6	17.1					
PE(x)	-60.0	41.7	36.7	31.6	26.4					
EV/EBITDA	-90.7	29.4	26.7	22.8	19.1					
BVPS	268.1	282.3	302.4	387.5	489.4					
FCF	6.2	6.3	8.4	10.5	9.7					

	Mar-25	Dec-24	Sep-24
Promoters	66.26	66.26	66.26
Flls	8.86	9.26	9.11
DIIs	17.48	17.02	17.09
Public	7.38	7.46	7.52

Relative Performance (%)							
YTD	3Y	2Y	1Y				
BSE Healthcare	73.4	83.2	19.2				
AJP	56.2	108.3	21.3				



Maitri Sheth

Email: maitri.sheth@choiceindia.com Ph: +91 22 6707 9511

Deepika Murarka

Email: Deepika.murarka@choiceindia.com Ph: +91 22 6707 9513

Expansion-Driven Margin Pause; BUY on Strong Pipeline

AJP is currently in an investment phase, expanding its presence across geographies and therapeutic areas. As a result, the company expects *higher promotional and employee expenses*, which *will likely cap EBITDA margin* improvements until post-FY27E. Reflecting this outlook, we have revised our FY26E/FY27E earnings estimates downward by 6.2%/6.1%, respectively. However, we maintain our **BUY** rating on the stock and revise our target price to **INR 3,180** (revised down from INR 3,667 in Q3FY25) by averaging our PE-based

and DCF-based valuations. For the PE method, we apply a multiple of 30x on FY27E EPS, (in line with comparable generics peers in terms of growth, returns, and margins). Our DCF-based valuation (*refer Exhibit 1*) suggests a slightly higher upside, but we believe the blended approach offers a more balanced view of near- and long-term value drivers.

Revenue Beat Led by US Generics; EBITDA Margin and PAT Below Estimates: Revenue grew 11.0% YoY / 2.1% QoQ to INR 11.7 Bn (vs. consensus estimate: INR 11.4 Bn), driven by strong US generics growth (up 24.5% YoY / 23.6% QoQ). EBITDA rose 6.8% YoY but declined 7.4% QoQ to INR 2.9 Bn; margins contracted 102 bps YoY / 260 bps QoQ to 25.4% (vs. consensus: 28.0%). PAT increased 11.1% YoY but declined 3.3% QoQ to INR 2.3 Bn (vs. consensus estimate: INR 2.9 Bn).

US Generics Set for High-Teen Growth on Strong Launch Pipeline: US generics delivered strong growth during the quarter, driven by solid market execution and new product launches. The company launched four new products—Oxtellar XR (launched as an authorized generic from Supernus), Fluvoxamine ER, and two undisclosed molecules—which are expected to support growth in FY26. Additionally, the company plans to launch seven more products in FY26. With a strong pipeline and the ramp-up of recent launches, we expect US generics to maintain strong momentum, in line with management's guidance of high-teen growth.

Asia Branded Generics to Grow 15% in FY26; Segment Outlook Remains Positive: Branded generics (Asia + Africa) now account for 41.8% of total revenue. The company launched 25 new products in the Asia branded segment and 13 in Africa, with a primary focus on chronic therapies. We expect Asia branded generics to maintain strong momentum, growing at 15% in FY26, while growth in the Africa segment is likely to remain moderate amid a broader market slowdown. Overall, we project the branded generics segment to grow in the low double digits.

Particulars (INR Mn)	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)
Revenue	11,704	10,541	11.0	11,461	2.1
Cost of Goods Sold	2,834	2,644	7.2	2,578	9.9
Gross Margin (%)	75.8	74.9	87 bps	77.5	(172)bps
Operating Exxpenses	5,898	5,114	31.4	5,675	8.1
EBITDA	2,972	2,783	6.8	3,208	(7.4)
EBITDA Margin (%)	25.4	26.4	(102)bps	28.0	(260)bps
Depreciation	398	343	16.1	360	10.6
Interest	61	15	296.7	79	(23.3)
РВТ	2,694	2,781	(3.1)	3,074	(12.4)
Tax	442	753	(41.4)	745	(40.7)
PAT	2,253	2,027	11.1	2,329	(3.3)
EPS	18.0	16.0	12.0	18.6	(3.3)
Geographical Revenue	Q4FY25	Q4FY24	YoY (%)	Q3FY25	QoQ (%)
India	3,690	3,260	13.2	3,450	7.0
North America	3,250	2,610	24.5	2,630	23.6
Africa Branded Generics	1,330	1,130	17.7	1,730	(23.1)
Asia Branded Generics	3,030	2,810	7.8	3,160	(4.1)
Africa Institutional	280	610	(54.1)	330	(15.2)

124

121

2.6

Source: Company, CEBPL

(23.1)

161

Others

US Generics

- The company launched Oxtellar XR as an authorized generic and plans to transition to its own ANDA after the contract ends.
- The business plans to launch seven new products in FY26 and file 10– 12 ANDAs during the year.
- Ajanta maintains a strong supply record and aims to scale up recently launched products in FY26.

India Business

- Two new therapies, gynecology and nephrology, were added along with 450 new medical representatives in FY25.
- The company acquired three brands in the pain management segment
 - India business launched 32 new products in FY25, including 8 first-time launches in the country.

Branded Generics (Asia + Africa)

- The company is not entering any new large markets in the near term but plans to deepen its presence in existing geographies.
- The Asia business, with presence in nearly 10 countries, supported by 25 new product launches.
- The Africa branded generics business grew 28%, driven by focus on chronic therapies and 13 new launches.

Africa Institutional

- This segment contributed only 3% to total revenue and remains highly unpredictable due to dependency on procurement agencies and donor funding.
- Ajanta does not expect visibility or consistent contribution from this segment going forward.

Outlook

- The US generics business is expected to grow in the mid-to-high teens in FY26, driven by full-year contribution from recent launches and additional new product introductions.
- India growth is expected to be ~200bps more than the IPM growth.
- The branded generics business is expected to deliver low-teens growth in FY26, supported by continued momentum in Asia, and Africa.
- EBITDA margin for FY26 is guided at around 28% plus or minus 1%, taking into account increased investment in field force and promotional activities.
- R&D spending will remain at around 5% of total revenue, equally split between US filings and branded generics for India and emerging markets.
- Capital expenditure for FY26 is expected to be INR 3,000 Mn, including spending on the new liquid plant at Pithampur and office infrastructure.


- EBITDA margin is expected to remain around FY25 levels at ~28%, impacted by higher promotional spending.
- Capex for FY26 is estimated at ~INR 3,000 Mn.
- R&D focus remains strong, with ~50% of expenses allocated toward building the US product pipeline.

Quarterly Trends


Choice

Q4FY25 Results Update


Q4FY25 Segment Revenue Split (INR 11.7 Bn)



Strong Market Execution Drives Growth for US Generics




Source: Company, CEBPL



Revenue Surges Ahead of Street Estimates


Source: Company, CEBPL


Business Mix Shift Leads to Gross Margin Dip



Source: Company, CEBPL

PAT Falls Short of Street Estimates





EBITDA Miss on Higher Promotional Expenses


Source: Company, CEBPL

Source: Company, CEBPL


Annual Trends


Choice

Revenue to Grow at 11.9% CAGR FY24-27E



Source: Company, CEBPL






Choice Equity Broking Pvt. Ltd.—Research Analyst - INH000000222 | Email: institutional.equities@choiceindia.com


PAT to Grow Slightly, In Line with EBITDA

US Growth Driven by Strong Product Pipeline




Source: Company, CEBPL

Subdued EBITDA Margin Growth Expected



ROE and ROIC



Source: Company, CEBPL

Source: Company, CEBPL

Exhibit 1: DCF (Consolidated in INR Mn)

Particular	FY25	FY26E	FY27E	FY28E	FY29E	FY30E
Revenue Drivers						
India	14,520	16,262	18,539	20,393	22,024	23,786
North America	10,470	12,041	13,967	15,364	16,593	17,588
Africa Branded Generic	7,500	8,625	9,919	10,911	11,783	12,726
Asia Branded Generic	11,910	13,697	15,751	17,326	18,712	20,022
Africa Institutional	1,470	588	235	94	38	15
Others	611	600	600	600	600	600
Total Revenue	46,481	51,812	59,011	64,688	69,751	74,738
EBIT	11,154	13,031	15,593	17,466	18,833	20,179
EBIT Margin (%)	24.0%	25.2%	26.4%	27.0%	27.0%	27.0%
NOPAT	8,633	9,773	11,695	13,099	14,124	15,134
Depreciation and Amortisation	1,441	1,606	1,771	1,824	1,879	1,935
Change in Working Capital	-204	936	-1,299	-1,429	-1,572	-1,729
Capital Expenditure	3,179	3,000	3,000	2,000	2,000	2,000
FCFF	13,049	15,316	15,167	15,495	16,432	17,341
Discounted Cash Flows		13,805	12,322	11,347	10,846	10,317

Particular	
WACC (%)	10.9%
Terminal Growth Rate (%)	2.5%
Cost of Equity (%)	10.9%
Cash Flow in Terminal Year (FY30)	17,341
Terminal Value	2,10,519
PV of Terminal Value	3,53,830
EV	4,12,468
Net Debt	-1,737
Equity Value	4,14,205
Equity Value Per Share	3,304

Sensitivity Analysis

	Terminal Growth Rate								
		1.5%	2.0%	2.5%	3.0%	3.5%			
	9.9%	3,165	3,348	3,554	3,791	4,064			
	10.4%	3,068	3,234	3,421	3,633	3,876			
WACC	10.9%	2,981	3,134	3,304	3,497	3,715			
	11.4%	2,903	3,044	3,201	3,377	3,574			
	11.9%	2,833	2,965	3,109	3,271	3,451			

Source: Company, CEBPL

Source: Company, CEBPL

Income statement (Consolidated in INR Mn)

Particular	FY23	FY24	FY25	FY26E	FY27E				
Revenue	37,426	42,087	46,481	51,812	59,011				
Gross Profit	26,922	31,421	35,773	39,896	45,689				
EBITDA	(3,714)	11,543	12,595	14,637	17,364				
Depreciation	1,308	1,354	1,441	1,606	1,771				
EBIT	(5,022)	10,189	11,154	13,031	15,593				
Other Income	986	1,022	945	1,347	1,534				
Interest Expense	58	72	207	150	100				
РВТ	(4,094)	11,138	11,892	14,228	17,027				
Reported PAT	(5,667)	8,161	9,204	10,671	12,770				
EPS	(45)	65	73	85	102				

Ratio Analysis	FY23	FY24	FY25	FY26E	FY27E
Growth Ratios					
Revenues	12.0	12.5	10.4	11.5	13.9
EBITDA	(179.0)	(410.8)	9.1	16.2	18.6
PBT	(191.0)	(372.0)	6.8	19.6	19.7
PAT	(323.8)	(244.0)	12.8	15.9	19.7
Margins					
Gross Profit Margin	71.9	74.7	77.0	77.0	77.4
EBITDA Margin	(9.9)	27.4	27.1	28.3	29.4
PBT Margin	(10.9)	26.5	25.6	27.5	28.9
Tax Rate	(38.4)	26.7	22.6	25.0	25.0
PAT Margin	(15.1)	19.4	19.8	20.6	21.6
Profitability					
Return On Equity (ROE)	(16.7)	22.9	24.3	22.0	20.8
Return On Invested Capital (ROIC)	(22.8)	24.5	25.2	27.1	25.9
Return On Capital Employed (ROCE)	(12.1)	17.6	18.4	17.6	17.1
Financial leverage					
OCF/EBITDA (x)	(2.6)	0.9	1.1	1.2	1.0
OCF / Net profit (x)	(1.4)	1.0	1.3	1.3	1.0
EV/EBITDA (x)	(88.0)	28.5	26.7	22.8	19.1
Earnings					
EPS	(44.9)	64.6	73.4	85.1	101.9
Shares Outstanding	126.4	126.4	125.4	125.4	125.4
Working Capital					
Inventory Days (x)	80	72	71	64	63
Receivable Days (x)	103	108	93	80	75
Creditor Days (x)	41	40	36	36	35
Working Capital Days	141	140	128	108	103

Source: Company, CEBPL

Balance sheet (Consolidated in INR Mn)

Cash Flows From Investing

Cash Flows From Financing

DuPont Analysis (INR Mn)

ROE

Net Profit Margin

Asset Turnover

Financial Leverage

Source: Company, CEBPL

Particular	FY2	3	FY24	FY25	FY26E	FY27E
Net Worth	33,88) 3	5,674	37,903	48,574	61,344
Borrowings	35	5	353	474	454	434
Trade Payables	4,22	3	4,632	4,542	5,110	5,659
Other Non-current Liabilities	1,250	5	1,518	1,938	1,660	1,735
Other Current Liabilities	7,07	1	4,208	5,292	5,003	5,362
Total Net Worth & Liabilities	46,78	34	6,384	50,150	60,802	74,534
Net Block	14,078	31	3,841	16,249	17,643	18,871
Capital WIP	2,09	5	2,565	1,763	1,763	1,763
Goodwill & Intangible Assets	78	3	147	465	465	465
Investments	5,354	4	3,486	4,640	12,169	17,956
Trade Receivables	10,56	91	2,468	11,827	11,356	12,126
Cash & Cash Equivalents	3,30	9	1,308	1,762	3,356	6,107
Other Non-current Assets	1,94	9	2,337	2,990	2,136	2,191
Other Current Assets	9,35	31	0,233	10,453	11,914	15,056
Total Assets	46,78	34	6,384	50,150	60,802	74,534
Cash Flows (INR Mn)		FY23	FY	24 FY:	25 FY26I	FY27E
Cash Flows From Operatio	ns	7,922	7,8	51 11,5	72 13,53	6 12,713

(5,596)

FY23

(16.7%)

(15.1%)

0.8

1.4

(1,082) (10,511)

654

FY24

22.9%

19.4%

0.9

1.3

(3,765) (10,530)

(7,334)

FY25

24.3%

19.8%

0.9

1.3

(1,414)

FY26E

22.0%

20.6%

0.9

1.3

(8,786)

(1,176)

FY27E

20.8%

21.6%

0.8

1.2

	1
	5
	0
	2
	2
	-
	_
	C
	-
	-
	es Se
	U
	œ
	25
	0
	2.2
	≻
	Γ.
	1
	-
	4
	С
	0

Choice

Historical share price chart: Ajanta Pharma Limited



Date	Rating	Target Price
May 7, 2023	ADD	1,412
July 28,2023	ADD	1,730
November 1, 2023	ADD	1,943
February 2, 2024	ADD	2,340
May 3, 2024	BUY	2,676
July 31, 2024	BUY	2,758
October 29, 2024	BUY	3,305
January 31, 2025	BUY	3,667

Institutional Research Team			
Utsav Verma, CFA	Head of Research – Institutional Equities	utsav.verma@choiceindia.com	+91 22 6707 9440
Prashanth Kumar Kota, CFA	Analyst – Basic Materials / Real Estate & Infra	prashanth.kota@choiceindia.com	+91 22 6707 9887
Deepika Murarka	Analyst – Pharmaceuticals / Healthcare	deepika.murarka@choiceindia.com	+91 22 6707 9513
Ashutosh Murarka	Analyst – Cement	ashutosh.murarka@choiceindia.com	+91 22 6707 9887
Putta Ravi Kumar	Analyst – Defense	ravi.putta@choiceindia.com	+91 22 6707 9908
Aayush Saboo	Analyst – Real Estate & Infrastructure	aayush.saboo@choiceindia.com	+91 22 6707 9512
Maitri Sheth	Analyst – Pharmaceuticals / Healthcare	maitri.sheth@choiceindia.com	+91 22 6707 9511
Nikhil Kamble	Sr. Associate – Consumer Retail	nikhil.kamble@choiceindia.com	+91 22 6707 9513
Bharat Kumar Kudikyala	Associate – Building Material	bharat.kudikyala@choiceindia.com	+91 22 6707 9887
Karan Kamdar	Analyst – SMID	karan.kamdar@choiceindia.com	+91 22 6707 9930
Vinay Rawal	Associate – SMID	vinay.rawal@choiceindia.com	+91 22 6707 9887
Heet Chheda	Associate – Automobile	heet.chheda@choiceindia.com	+91 22 6707 9952
Aryan Goyal	Associate – Automobile	aryan.goyal@choiceindia.com	+91 22 6707 9517
Rushil Katiyar	Associate – Information Technology	rushil.katiyar@choiceindia.com	+91 22 6707 9887
Sumit Pandey	Executive – SMID	pandey.sumit@choiceindia.com	+91 22 6707 9887

CHOICE RATING DISTRIBUTION & METHODOLOGY

Large Cap*	
BUY	The security is expected to generate upside of 15% or more over the next 12 months
ADD	The security is expected to show upside returns from 5% to less than 15% over the next 12 months
REDUCE	The security is expected to show upside or downside returns by 5% to -5% over the next 12 months
SELL	The security is expected to show downside of 5% or more over the next 12 months
Mid & Small Cap*	
BUY	The security is expected to generate upside of 20% or more over the next 12 months
ADD	The security is expected to show upside returns from 5% to less than 20% over the next 12 months
REDUCE	The security is expected to show upside or downside returns by 5% to -10% over the next 12 months
SELL	The security is expected to show downside of 10% or more over the next 12 months
Other Ratings	
NOT RATED (NR)	The stock has no recommendation from the Analyst
UNDER REVIEW (UR)	The stock is under review by the Analyst and rating may change
Sector View	
POSITIVE (P)	Fundamentals of the sector look attractive over the next 12 months
NEUTRAL (N)	Fundamentals of the sector are expected to be consistent over the next 12 months
CAUTIOUS (C)	Fundamentals of the sector are expected to be challenging over the next 12 months
*Lorge Con: More Then INP 20	000Cr Market Con

*Large Cap: More Than INR 20,000Cr Market Cap *Mid & Small Cap: Less Than INR 20,000Cr Market Cap

Disclaimer

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Choice Equity Broking Private Limited-Research Analyst - INH000000222. (CIN. NO.: U65999MH2010PTC198714). Reg. Add.: Sunil Patodia Tower, J B Nagar, Andheri(East), Mumbai 400099. Tel. No. 022-6707 9999

Compliance Officer--Prashant Salian, Email Id - Prashant.salain@choiceindia.com Contact no. 022- 67079999- Ext-2310

Grievance officer-Deepika Singhvi Tel.022-67079999- Ext-834. Email- ig@choiceindia.comm

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

This Research Report (hereinafter referred as "Report") has been prepared by Choice Equity Broking Private Limited as a Research Entity (hereinafter referred as "CEBPL RE" Limited. The Research Analysts, strategists are principally responsible for the preparation of "CEBPL RE" research. The research analysts have received compensation based upon various factors, which may include quality of research, investor client feedback, stock picking, competitive factors and firm revenues etc.

Whilst CEBPL has taken all reasonable steps to ensure that this information is correct, CEBPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his or her own risk and CEBPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

General Disclaimer: This 'Report' is strictly meant for use by the recipient and is not for circulation. This Report does not take into account particular investment objectives, financial situations or specific needs of individual clients nor does it constitute a personal recommendation. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through CEBPL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein.

Institutional Equities

Choice

These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this "Report" should rely on information/data arising out of their own Study/investigations. It is advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This 'Report' has been prepared on the basis of publicly available information, internally developed data and other sources believed by CEBPL to be reliable. CEBPL or its directors, employees, affiliates or representatives shall not be responsible for, or warrant for the accuracy, completeness, adequacy and reliability of such information / opinions / views. Though due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or CEBPL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this report.

The price and value of the investments referred to in this Report and the income from them may tend to go down as well as up, and investors may incur losses on any investments. Past performance shall not be a guide for future performance. CEBPL does not provide tax advice to its clients, and all investors are strongly advised to take advice of their tax advisers regarding taxation aspects of any potential investment. Opinions are based on the current scenario as of the date appearing on this 'Report' only. CEBPL does not undertake to advise you as to any change of our views expressed in this "Report' may differ on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold CEBPL, its employees and associates responsible for any losses, damages of any type whatsoever.

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject "CEBPL RE" to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by "CEBPL RE" in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this "Report" shall not be possessed, circulated and/or distributed in any such country or jurisdiction of such country or jurisdiction. "CEBPL" requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to "CEBPL". Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in Mumbai (India). Statements on ownership and material conflicts of interest, compensation - CEBPL and Associates reciprocates to the best of the knowledge and belief of CEBPL/ its Associates/ research Analyst who is preparing this report.

Disclosures of Interest (Additional):

- 1. "CEBPL", its research Analyst(s), or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in this report.
- 2. "CEBPL" its research Analyst, or its associates or relatives of the research analyst affiliates collectively do not hold more than 1 of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- 3. "CEBPL", its research analyst, his/her associate, his/her relative, do not have any other material conflict of interest at the time of publication of this research report.
- 4. "CEBPL", its research analyst, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
- "CEBPL", its research analyst, or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report.
- 7. "CEBPL, or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
- 8. CEBPL research analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Research report.
- 9. "CEBPL", its research analyst has not been engaged in market making activity for the company(ies) covered in the Research report.

Details of Associates of CEBPL and Brief History of Disciplinary action by regulatory authorities are available on our

website i.e. https://choiceindia.com/research-listing

Sr. No.	Particulars	Yes / No
1.	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by CEBPL	No
2	Whether Research Analyst, CEBPL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1 of the company(ies) covered in the Research report	No
3.	Whether compensation has been received by CEBPL or its associates from the company(ies) covered in the Research report	No
4.	CEBPL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report	No
5.	CEBPL, its research analyst, his associate, or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve months	No

Copyright: The copyright in this research report belongs exclusively to CEBPL. All rights are reserved. Any unauthorized use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the CEBPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

This "Report" is for distribution only under such circumstances as may be permitted by applicable law. This "Report" has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This "Report" is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CEBPL nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this "report" or lack of care in this report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Information barriers may be relied upon by CEBPL, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CEBPL.

Investing in any non-U.S. securities or related financial instruments (including ADINR) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign comparable to those in effect within the United States. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CEBPL with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of CEBPL and CEBPL accepts no liability whatsoever for the actions of third parties in this respect.

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Research report are given above.